The Immunopathogenesis of IBD:
An Integrated View of Integrins and Adhesins


Clinicians and other healthcare providers with an interest in IBD are aware of the limitations of anti-TNFα therapy, but there are limited alternative options available. This limits the opportunity to optimize outcomes in patients with moderate-to-severe IBD.
In order to fully assess novel therapies such as the integrin inhibitors, it is necessary to be fully conversant with the rationale and mechanism of action, as well as the clinical evidence to date. This multi-program initiative seeks to arm healthcare providers with an essential update and insight into how novel therapies for IBD might be included in future management paradigms.

Target Audience

This activity has been designed to meet the educational needs of physicians and registered nurses involved in the management of patients with inflammatory bowel disease.


Please also take this opportunity to view the certified pre-symposium activity at: (registration to IBDWG required)